| scholarly article | Q13442814 |
| P2093 | author name string | Ravi Radhakrishnan | |
| Shannon E Telesco | |||
| Andrew Shih | |||
| Yingting Liu | |||
| P2860 | cites work | Comparative Modeling in Structural Genomics | Q57972065 |
| Computer simulations of protein folding by targeted molecular dynamics | Q73594418 | ||
| Software news and updates. Carma: a molecular dynamics analysis program | Q80135906 | ||
| Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer | Q81378656 | ||
| Mapping hydrophobicity at the nanoscale: applications to heterogeneous surfaces and proteins | Q82274350 | ||
| Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck | Q82879823 | ||
| Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone r | Q83868334 | ||
| Advances in Homology Protein Structure Modeling | Q22241408 | ||
| An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 | ||
| EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization | Q24296900 | ||
| HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors | Q24297102 | ||
| Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha | Q24307630 | ||
| Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment | Q24309071 | ||
| Mechanism of activation and inhibition of the HER4/ErbB4 kinase | Q24310089 | ||
| The Protein Data Bank | Q24515306 | ||
| The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand | Q24536067 | ||
| EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 | ||
| ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation | Q24621754 | ||
| Large-scale protein structure modeling of the Saccharomyces cerevisiae genome | Q24654088 | ||
| Phosphotyrosine interactome of the ErbB-receptor kinase family | Q24672516 | ||
| Knowledge-based model building of proteins: concepts and examples | Q24676038 | ||
| Structure of the extracellular region of HER3 reveals an interdomain tether | Q27639450 | ||
| Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor | Q27639528 | ||
| Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 | ||
| The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors | Q27640631 | ||
| The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain | Q27646344 | ||
| Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 | Q27646596 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies | Q27851393 | ||
| All-atom empirical potential for molecular modeling and dynamics studies of proteins | Q27860468 | ||
| Cell signaling by receptor tyrosine kinases | Q27860474 | ||
| VMD: visual molecular dynamics | Q27860554 | ||
| Comparative protein structure modeling of genes and genomes | Q27860712 | ||
| Scalable molecular dynamics with NAMD | Q27860718 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| The conformational plasticity of protein kinases | Q27860946 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| Protein tyrosine kinase structure and function | Q28145008 | ||
| Pairwise sequence alignment below the twilight zone | Q28205176 | ||
| Modeller: generation and refinement of homology-based protein structure models | Q28236254 | ||
| Molecular dynamics and protein function | Q28248486 | ||
| A new therapeutic antibody masks ErbB2 to its partners | Q28257173 | ||
| A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells | Q28282744 | ||
| Dynamics of folded proteins | Q28287584 | ||
| Comparative modeling for protein structure prediction | Q28299788 | ||
| Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes | Q28305615 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models | Q29616389 | ||
| Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism | Q29616720 | ||
| Essential dynamics of proteins | Q29616843 | ||
| EGF-ERBB signalling: towards the systems level | Q29619032 | ||
| Sequence comparison and protein structure prediction. | Q30354495 | ||
| Protein structure prediction and model quality assessment | Q30374023 | ||
| Homology modelling by distance geometry | Q30426762 | ||
| c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function | Q30442374 | ||
| Mechanism of biological synergy between cellular Src and epidermal growth factor receptor | Q30454480 | ||
| Extending the accuracy limits of prediction for side-chain conformations | Q30998288 | ||
| Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer | Q33511035 | ||
| Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing | Q33609045 | ||
| Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms | Q33968222 | ||
| Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study | Q34010366 | ||
| Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation | Q34166390 | ||
| In silico evidence for DNA polymerase-beta's substrate-induced conformational change | Q34187645 | ||
| Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions | Q34243228 | ||
| Lung cancer: intragenic ERBB2 kinase mutations in tumours | Q34354426 | ||
| Dynamics of biochemical and biophysical reactions: insight from computer simulations | Q34536703 | ||
| ErbB receptors: new insights on mechanisms and biology | Q34579265 | ||
| Phosphoproteomic analysis of Her2/neu signaling and inhibition | Q34772747 | ||
| Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials | Q35051978 | ||
| Structure/function correlations of proteins using MM, QM/MM, and related approaches: methods, concepts, pitfalls, and current progress | Q35590761 | ||
| A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies | Q35597532 | ||
| Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity | Q35641650 | ||
| Coupling of fast and slow modes in the reaction pathway of the minimal hammerhead ribozyme cleavage | Q35972956 | ||
| Modelling enzyme reaction mechanisms, specificity and catalysis. | Q36299121 | ||
| Progress in modeling of protein structures and interactions | Q36299253 | ||
| Resistance to Trastuzumab in Breast Cancer. | Q36318226 | ||
| Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer | Q36332052 | ||
| Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. | Q36667508 | ||
| Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. | Q36710542 | ||
| A helix scaffold for the assembly of active protein kinases | Q36871421 | ||
| Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 | ||
| Molecular dynamics simulations reveal that Tyr-317 phosphorylation reduces Shc binding affinity for phosphotyrosyl residues of epidermal growth factor receptor | Q37279304 | ||
| Characterizing hydrophobicity of interfaces by using cavity formation, solute binding, and water correlations | Q37340718 | ||
| Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer | Q37683189 | ||
| ERBB2 kinase domain mutation in the lung squamous cell carcinoma | Q38513518 | ||
| Free energy via molecular simulation: applications to chemical and biomolecular systems | Q38648060 | ||
| A new method for building protein conformations from sequence alignments with homologues of known structure | Q39101556 | ||
| Single mutation induced H3N2 hemagglutinin antibody neutralization: a free energy perturbation study | Q39987453 | ||
| EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer | Q40235641 | ||
| Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells | Q40361259 | ||
| Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. | Q40449400 | ||
| Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. | Q40473008 | ||
| Computer simulation of the chemical catalysis of DNA polymerases: discriminating between alternative nucleotide insertion mechanisms for T7 DNA polymerase | Q40577548 | ||
| Biomolecular free energy profiles by a shooting/umbrella sampling protocol, "BOLAS" | Q42080174 | ||
| Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases | Q42822469 | ||
| An automated method for modeling proteins on known templates using distance geometry | Q42842890 | ||
| Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer | Q44912057 | ||
| Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer | Q46610979 | ||
| Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism | Q46881384 | ||
| Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential | Q47814156 | ||
| Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer | Q48142933 | ||
| A sequence alignment algorithm with an arbitrary gap penalty function | Q49219249 | ||
| An efficient method for sampling the essential subspace of proteins. | Q52310950 | ||
| Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. | Q53606400 | ||
| ERBB2 kinase domain mutation in a gastric cancer metastasis. | Q53609172 | ||
| Molecular dynamics: applications to proteins | Q57000574 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 1-35 | |
| P577 | publication date | 2011-01-01 | |
| P1476 | title | Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation | |
| P478 | volume | 4 |
| Q35111697 | A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network |
| Q37602884 | Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype |
| Q36181814 | Structural systems biology and multiscale signaling models |
Search more.